Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lier Chemical Co.,LTD. (002258.SZ)
Mianyang, CN
Established in 1993 and based in Mianyang, China, Lier Chemical Co.,LTD. functions as a comprehensive entity focused on the research, development, manufacturing, and worldwide distribution of agrochemical products. The company's diverse product line encompasses a selection of low-toxicity and low-residue pesticides, including prominent examples such as chloropyridines and organophosphates. Its extensive offerings for crop protection also feature numerous herbicides, specifically pinoxaden, glufosinate-ammonium, diquat, flumioxazin, clodinafop-propargyl, clopyralid acid, picloram, fluroxypyr-meptyl, triclopyr, diuron, bensulfuron-methyl, linuron, pyrazosulfuron-ethyl, nicosulfuron, flufenacet, mefenacet, and quinclorac. Additionally, Lier Chemical provides fungicides like azoxystrobin, epoxiconazole, iprodione, and difenoconazole, alongside insecticides such as chlorpyrifos and pyriproxyfen. Beyond its agricultural chemical focus, the company produces active pharmaceutical ingredients (APIs) and their respective formulations. A substantial part of its business involves the synthesis of a broad spectrum of chemical intermediates, most notably pyridine derivatives including 2-chloropyridine, 2,3-dichloropyridine, 2,5-dichloropyridine, 2,6-dichloropyridine, 2,3,4-trichloropyridine, 2,3,5-trichloropyridine, 2,3,6-trichloropyridine, nitrapyrin, pentafluoropyridine, 2,3,5,6-tetrachloro-4-methylsulfonylpyridine, 6-chloropyridine-2-carbonitrile, 3,6-difluoropyridine-2-carboxylic acid, 2,2'-bipyridine, 2-chloro-4'-fluoroacetophenone, 2-chloro-2',4'-difluoroacetophenone, and 2-fluoro-3-nitrobenzoic acid. Other specialized intermediates manufactured include (E)-4-(dimethylamino)but-2-enoic acid hydrochloride, 4,4'-dichloro-[3,3']bipyridinyl, clopyralid-methyl, methyl 3,4,6-trichloropicolinate, 2,4,5-trichloropyridine, 7-fluoro-6-nitro-4-hydroxyquinazoline, N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine, 4-bromocrotonic acid, 4-N-(3-chloro-4-fluorophenyl)-7-[(3S)-oxolan-3-yl]oxyquinazoline-4,6-diamine, 2-amino-N-(2-chloro-6-methylphenyl)-1,3-thiazole-5-carboxamide, and 5-chloro-8-hydroxyquinoline.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.97% | +3.33% | -4.09% | -25.79% | -3.19% | -4.75% | +4.81% | -7.24% | -26.49% | +100.81% | +95.13% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%+23.2% ★ Q1'26: +10.9% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+122.2% ★ Q1'26: -26.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+1.2% Q1'26: -25.6% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+8.0% ★ Q1'26: +8.1% (vs Q1'25)
-
ROIC Chemicals: +3.4%+3.9% ★ Q1'26: +4.6% (vs Q1'25)
-
Share dilution Chemicals: +0.0%0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×3.13× Q1'26: 7.05× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.49B
est: 1.64B (-9.0%)
|
1.98B
est: 1.98B (+0.0%)
|
3.08B
est: 3.08B (0.0%)
|
4.03B
est: 4.08B (-1.3%)
|
4.16B
est: 4.24B (-1.9%)
|
4.97B
est: 5.04B (-1.3%)
|
6.49B
est: 6.18B (+5.1%)
|
10.14B
est: 10.11B (+0.2%)
|
7.85B
est: 8.01B (-2.0%)
|
7.31B
est: 6.52B (+12.1%)
|
9.01B
est: 8.66B (+4.1%)
|
10.26B
9.86B – 10.67B
+18.6% YoY
|
11.18B
10.33B – 12.03B
+8.9% YoY
|
12.30B
11.58B – 13.02B
+10.0% YoY
|
| EBITDA |
277.21M
est: 390.08M (-28.9%)
|
385.98M
est: 472.58M (-18.3%)
|
716.68M
est: 735.34M (-2.5%)
|
1.06B
est: 972.44M (+8.7%)
|
842.04M
est: 1.01B (-16.8%)
|
1.26B
est: 1.20B (+5.3%)
|
1.91B
est: 1.47B (+29.4%)
|
2.93B
est: 2.41B (+21.5%)
|
1.53B
est: 1.91B (-20.0%)
|
1.17B
est: 1.45B (-18.9%)
|
1.54B
est: 1.92B (-19.9%)
|
2.28B
2.19B – 2.37B
+18.6% YoY
|
2.48B
2.29B – 2.67B
+8.9% YoY
|
2.73B
2.57B – 2.89B
+10.0% YoY
|
| EBIT |
167.88M
est: 258.77M (-35.1%)
|
241.63M
est: 313.49M (-22.9%)
|
532.54M
est: 487.80M (+9.2%)
|
797.44M
est: 645.08M (+23.6%)
|
495.84M
est: 671.33M (-26.1%)
|
875.53M
est: 796.65M (+9.9%)
|
1.41B
est: 977.65M (+44.3%)
|
2.37B
est: 1.60B (+48.1%)
|
902.16M
est: 1.27B (-28.8%)
|
356.08M
est: 905.93M (-60.7%)
|
721.77M
est: 1.20B (-40.0%)
|
1.43B
1.37B – 1.48B
+18.6% YoY
|
1.55B
1.43B – 1.67B
+8.9% YoY
|
1.71B
1.61B – 1.81B
+10.0% YoY
|
| Net Income |
138.45M
est: 191.27M (-27.6%)
|
208.35M
est: 227.00M (-8.2%)
|
401.97M
est: 397.40M (+1.2%)
|
577.81M
est: 651.85M (-11.4%)
|
311.14M
est: 357.72M (-13.0%)
|
612.21M
est: 644.91M (-5.1%)
|
1.07B
est: 1.13B (-5.1%)
|
1.81B
est: 1.89B (-4.2%)
|
603.89M
est: 682.43M (-11.5%)
|
215.34M
est: 216.12M (-0.4%)
|
478.77M
est: 492.27M (-2.7%)
|
621.68M
613.60M – 629.75M
+26.3% YoY
|
740.40M
694.91M – 785.90M
+19.1% YoY
|
850.06M
785.49M – 914.64M
+14.8% YoY
|
| SGA |
180.23M
est: 102.71M (+75.5%)
|
219.51M
est: 124.44M (+76.4%)
|
242.42M
est: 193.63M (+25.2%)
|
359.42M
est: 256.06M (+40.4%)
|
340.22M
est: 266.48M (+27.7%)
|
349.23M
est: 316.22M (+10.4%)
|
374.02M
est: 388.07M (-3.6%)
|
480.40M
est: 634.87M (-24.3%)
|
559.54M
est: 503.02M (+11.2%)
|
492.55M
est: 317.68M (+55.0%)
|
—
est: 421.80M (-100.0%)
|
500.09M
480.27M – 519.92M
+18.6% YoY
|
544.64M
503.20M – 586.08M
+8.9% YoY
|
599.20M
564.19M – 634.22M
+10.0% YoY
|
| EPS |
0.20
est: 0.24 (-16.3%)
|
0.29
est: 0.28 (+0.8%)
|
0.55
est: 0.50 (+10.8%)
|
0.79
est: 0.81 (-3.0%)
|
0.42
est: 0.45 (-5.2%)
|
0.83
est: 0.81 (+3.0%)
|
1.46
est: 1.41 (+3.4%)
|
2.43
est: 2.36 (+2.8%)
|
0.75
est: 0.85 (-12.0%)
|
0.27
est: 0.27 (+0.0%)
|
0.60
est: 0.62 (-2.4%)
|
0.78
0.77 – 0.79
+26.3% YoY
|
0.93
0.87 – 0.98
+19.1% YoY
|
1.06
0.98 – 1.14
+14.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-28 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-25 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-11 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Agribusiness UCITS ETF ISAG.L | 0.04% | 194.8K | 0.55% |
| 2 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.03% | 137.2K | 0.49% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 379.9K | 0.39% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 66.6K | 0.46% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 359.8K | 0.06% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 223.7K | 0.29% |
| 7 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 130.3K | 0.28% |
| 8 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 6.0K | 0.44% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.2K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 25.2K | 0.26% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Feng Qiu | Deputy General Manager | — | male |
| Huihua Liu | Deputy General Manager | — | female |
| Jiang Li | GM & Non-Independent Director | — | male |
| Jun Liu | Deputy GM & Secretary of the Board of Directors | — | male |
| Ke Cheng | Deputy General Manager | — | male |
| Rongzhen Luo | Deputy General Manager | — | male |
| Xiao Li Yang | Accounting Supervisor | — | — |
| Xiaowei Liu | Deputy General Manager | — | male |
| Xuan Yan | Financial Director | — | male |
| Yanfei Li | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002258.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
